GO
Loading...

Enter multiple symbols separated by commas

Biotechnology

More

  • Healthcare takeover targets Friday, 19 Jun 2015 | 1:17 PM ET
    Healthcare takeover targets

    In terms of deal value, healthcare has logged the most M&A activity this year, according to Dealogic, after taking the top spot in both 2014 and 2013. CNBC's Morgan Brennan reports.

  • Suberbug-fighting startup Friday, 19 Jun 2015 | 11:47 AM ET
    Suberbug-fighting startup

    Seres Therapeutics has filed to go public, ticker MCRB (for microbiome). CNBC's Meg Tirrell explains why it has breakthrough therapy designation from the FDA.

  • Avalanche CEO: Disappointed in market's reaction of study

    Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.

  • The pharma sector is exciting, says Wells Fargo Wednesday, 10 Jun 2015 | 7:24 PM ET
    The pharma sector is exciting, says Wells Fargo

    Margaret Patel, senior portfolio manager & managing director at Wells Fargo Advantage Funds, explains why she likes U.S. pharmaceutical stocks.

  • Contrarian biotech play Tuesday, 26 May 2015 | 5:28 PM ET
    Contrarian biotech play

    David Seaburg of Cowen has a way to trade pharma stocks into the ASCO meeting. He breaks it down, with Stacey Gilbert of Susquehanna and Brian Sullivan.

  • CHICAGO, May 14- Genome pioneer J. Craig Venter's company has signed a broad collaboration agreement with the Cleveland Clinic to sequence and analyze de-identified blood samples from the health system's patients, the two parties said on Thursday. The deal is the latest in a string for Venter's La Jolla, California- based Human Longevity Inc, a start-up formed in...

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • Moderna Therapeutics No. 1 on Disruptor 50: Here's why Tuesday, 12 May 2015 | 11:43 AM ET
    Moderna Therapeutics No. 1 on Disruptor 50: Here's why

    Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.

  • COPENHAGEN, May 8- Investors have high hopes for Novozymes and the enzymes it makes to improve chemical processes in a variety of industries, but analysts warn of pitfalls in a growth strategy reliant on a biofuel sector still in its infancy and unproven farming biotechnology. Having built on mother company Novo's work in the 1940 s to produce biological...

  • CHICAGO, May 7- Could the one percent soon get to live twice as long as the rest of us- maybe even forever? Immortality may not be in the cards just yet, but exponential breakthroughs in technology and medicine will make possible lifespans of 150 years or more, according to Ken Dychtwald. American men live an average of two years longer than they did in 2000, and women...

  • Is the market leadership changing? Thursday, 30 Apr 2015 | 5:00 PM ET
    Is the market leadership changing?

    Are transport stocks and biotechs giving up their market leadership? Andrew Burkly of Oppenheimer and Rich Ross of Evercore ISI discuss with Brian Sullivan.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • Promising cancer drugs Friday, 17 Apr 2015 | 4:42 PM ET
    Promising cancer drugs

    The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.

  • This is what's driving biotech Wednesday, 8 Apr 2015 | 5:30 AM ET
    This is what's driving biotech

    Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.

  • Halftime's hottest trades today: BTU, FB, JPM & XBI Tuesday, 7 Apr 2015 | 2:00 PM ET
    Halftime's hottest trades today: BTU, FB, JPM & XBI

    Halftime's hottest trades today: 6 trades in 50 seconds. Exploring social media rallies, biotech's reversal, earnings season, Peabody Energy, and JP Morgan.

  • LONDON, April 1- A European project to streamline drug approvals moves up a gear next week when regulators sit down with the first company to have an experimental product assessed under a new flexible pilot scheme. In the United States, the Food and Drug Administration has introduced a successful "breakthrough" designation, which has speeded up approval of...

  • The next buzz in biotech Tuesday, 31 Mar 2015 | 11:30 AM ET
    The next buzz in biotech

    As gene therapy emerges in the biotech industry and Phil Nadeau, Cowen and Company Biotechnology Analyst, explains why it could be the next billion dollar industry.

  • Genfit sinks 31%, but CEO defends liver drug results Friday, 27 Mar 2015 | 3:30 PM ET
    A researcher works in a laboratory of French biopharmaceutical company Genfit, in Loos, northern France, Nov. 15, 2012.

    The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.

  • Will the biotech run resume? Friday, 27 Mar 2015 | 12:00 AM ET
    Will the biotech run resume?

    After a tough week for biotech stocks, David Seaburg of Cowen & Co. and Craig Johnson of Piper Jaffray call the next move.